A detailed history of Cambridge Trust CO transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Cambridge Trust CO holds 10 shares of REGN stock, worth $7,568. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10
Previous 157 93.63%
Holding current value
$7,568
Previous $137,000 93.43%
% of portfolio
0.0%
Previous 0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 30, 2024

SELL
$902.69 - $993.35 $132,695 - $146,022
-147 Reduced 93.63%
10 $9,000
Q4 2023

Jan 31, 2024

SELL
$775.18 - $881.7 $8,526 - $9,698
-11 Reduced 6.55%
157 $137,000
Q3 2023

Oct 26, 2023

BUY
$692.45 - $844.37 $7,616 - $9,288
11 Added 7.01%
168 $138,000
Q4 2022

Jan 09, 2023

BUY
$705.89 - $766.39 $2,823 - $3,065
4 Added 2.61%
157 $113,000
Q1 2022

May 12, 2022

SELL
$595.12 - $698.43 $8,331 - $9,778
-14 Reduced 8.38%
153 $107,000
Q4 2021

Feb 14, 2022

BUY
$543.48 - $670.97 $90,761 - $112,051
167 New
167 $106,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $81.1B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Cambridge Trust CO Portfolio

Follow Cambridge Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Trust CO with notifications on news.